

Eli Lilly and Company Limited

Lilly House
Basing View
Basingstoke
Hampshire
RG21 4FL

www.lilly.com/uk

Tel: +44 (0) 1256 315000

29 August 2025

VIA EMAIL

Rt Hon. Liam Byrne MP
Chair, Business and Trade Committee
House of Commons
London, SW1A 0AA

Dear Liam,

Thank you for writing to by Eli Lilly and Company Limited on 18th August in relation to the list price change of UK list price for Mounjaro (tirzepatide). Please find responses to your questions below.

This information is provided as the result of a direct enquiry from the Business and Trade Select Committee. The content is a non-promotional response to the questions posed in line with the UK ABPI Code of Practice.

1. Whether the price rises reported are accurate and when they will be introduced?

Lilly has increased the UK List price for doses of tirzepatide which will be effective from 1 September. The list price is the published price for the medicine, and the change brings the UK list price into line with the rest of Europe and other developed countries.

2. What impact the price rises will have on UK consumers and sales in the UK? In particular, how will the sudden price rise – and resultant necessity to stop the medication for some patients – impact their health?

Lilly does not set the price in the private market but instead charge a set wholesale price to private providers. Private providers choose the price at which they sell the product to patients and may include additional wrap-around services within their pricing. In parallel, we have reached an agreement with the NHS to ensure continued supply and patient access.

We are working with providers in the private market to maintain patient access post 1st September and expect these arrangements to be passed onto patients. We are already seeing providers respond in different ways to the list price change, with a range of options available for eligible private patients.

Under the ABPI code we are unable to provide any direct medical advice but advise patients to speak to their healthcare professional if they are looking to stop the medication.

3. What the justification for the sudden price rises are? Whether the possibility of US trade action stimulated the price rise?

The UK was one of the first countries where Lilly launched tirzepatide and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes.

Several factors in the environment have changed since we launched 18 months ago.

We have now reached an agreement with the NHS across the UK to maintain patient access while realigning the list price, addressing the disparity with pricing in European and other developed countries. Lilly also agrees with the policy objective expressed in the Executive Order that research costs for breakthrough medicines should be shared more fairly across developed countries. However, a Most Favoured Nation approach is not the answer to help patient affordability.

4. Whether price rises in the UK will impact prices in other countries? In particular, in the US?

This list price change only impacts the UK.

5. What Eli Lilly policy is on ensuring competitive pricing of its medication in the UK?

All medicine manufacturers will consider several factors when determining the price of a medicine including the potential value and impact of their treatments. It is not unusual for companies to adjust their prices, and Lilly always follows the appropriate processes with government, the NHS and our customers, to agree and communicate such changes.

Lilly does not determine prices set by providers in the private market but is working with providers to maintain patient access.

6. Whether there will be any price rises for Mounjaro for the NHS?

There is no price increase for the NHS. We have reached an agreement with the NHS to maintain patient access. We now want to work in partnership with the Government to expand NHS access, building on the commitments in the 10 Year Plan.

I hope this addresses your questions satisfactorily.

Yours sincerely,



Chris Stokes
President & General Manager,
Lilly UK, Ireland and Northern Europe